JP2014504258A - 選択的プロトン共役葉酸輸送体および葉酸受容体ならびにGARFTaseおよび/または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法 - Google Patents

選択的プロトン共役葉酸輸送体および葉酸受容体ならびにGARFTaseおよび/または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法 Download PDF

Info

Publication number
JP2014504258A
JP2014504258A JP2013533912A JP2013533912A JP2014504258A JP 2014504258 A JP2014504258 A JP 2014504258A JP 2013533912 A JP2013533912 A JP 2013533912A JP 2013533912 A JP2013533912 A JP 2013533912A JP 2014504258 A JP2014504258 A JP 2014504258A
Authority
JP
Japan
Prior art keywords
bond
carbon atoms
carbonyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013533912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504258A5 (cg-RX-API-DMAC7.html
Inventor
アレーム ガンジー,
ラリー エイチ. マザーリー,
Original Assignee
デュケイン ユニバーシティー オブ ザ ホリー スピリット
ウェイン ステート ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デュケイン ユニバーシティー オブ ザ ホリー スピリット, ウェイン ステート ユニバーシティー filed Critical デュケイン ユニバーシティー オブ ザ ホリー スピリット
Publication of JP2014504258A publication Critical patent/JP2014504258A/ja
Publication of JP2014504258A5 publication Critical patent/JP2014504258A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013533912A 2010-10-12 2011-10-10 選択的プロトン共役葉酸輸送体および葉酸受容体ならびにGARFTaseおよび/または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法 Pending JP2014504258A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/902,310 2010-10-12
US12/902,310 US20110082158A1 (en) 2008-10-01 2010-10-12 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
PCT/US2011/055584 WO2012051105A2 (en) 2010-10-12 2011-10-10 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same

Publications (2)

Publication Number Publication Date
JP2014504258A true JP2014504258A (ja) 2014-02-20
JP2014504258A5 JP2014504258A5 (cg-RX-API-DMAC7.html) 2014-11-27

Family

ID=45938910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013533912A Pending JP2014504258A (ja) 2010-10-12 2011-10-10 選択的プロトン共役葉酸輸送体および葉酸受容体ならびにGARFTaseおよび/または他の葉酸代謝酵素のインヒビター化合物、ならびにその使用方法

Country Status (5)

Country Link
US (1) US20110082158A1 (cg-RX-API-DMAC7.html)
EP (1) EP2627332A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014504258A (cg-RX-API-DMAC7.html)
CA (1) CA2813743C (cg-RX-API-DMAC7.html)
WO (1) WO2012051105A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537107A (ja) * 2014-12-02 2017-12-14 イーライ リリー アンド カンパニー 1−オキソ−1,2−ジヒドロイソキノリン−7−イル−(5−置換−チオフェン−2−イル)−スルホンアミド化合物、それらの化合物を含む製剤、がん治療におけるaicarft阻害剤としてのそれらの使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3253738A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028608A (en) * 1989-12-11 1991-07-02 The Trustees Of Princeton University N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
JPH03173890A (ja) * 1989-09-21 1991-07-29 Takeda Chem Ind Ltd ピロロ[2,3―d]ピリミジン誘導体,その製造法,用途及び中間体
JPH04117381A (ja) * 1989-12-20 1992-04-17 Takeda Chem Ind Ltd 縮合複素環化合物,その製造法,用途及び中間体
JPH0578362A (ja) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd 縮合複素環化合物,その製造法,用途及び中間体
JPH05186437A (ja) * 1991-08-21 1993-07-27 Eisai Co Ltd 縮合ピリミジン誘導体
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
JPH06172358A (ja) * 1991-12-27 1994-06-21 Takeda Chem Ind Ltd 縮合ピリミジン誘導体、その製造法および用途
JP2000516961A (ja) * 1996-08-30 2000-12-19 イーライ・リリー・アンド・カンパニー 非古典的ピロロ[2,3―d]ピリミジン抗葉酸物質
CN101195625A (zh) * 2007-12-06 2008-06-11 上海交通大学 用于抗肿瘤药物抗叶酸剂及其盐和中间体
US20100081676A1 (en) * 2008-10-01 2010-04-01 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920702621A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
US5939420A (en) * 1991-04-08 1999-08-17 Duquesne University Of The Holy Ghost Pyrrolo 2,3d!derivatives
ES2207277T3 (es) * 1998-09-04 2004-05-16 Agouron Pharmaceuticals, Inc. Compuestos utiles como inhibidores de aircraft.
EP1424336A4 (en) * 2001-09-03 2004-11-10 Takeda Chemical Industries Ltd 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
US20050153989A1 (en) * 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US8030319B2 (en) * 2005-02-10 2011-10-04 Duquesne University Of The Holy Ghost Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2 3-d]pyrimidines

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03173890A (ja) * 1989-09-21 1991-07-29 Takeda Chem Ind Ltd ピロロ[2,3―d]ピリミジン誘導体,その製造法,用途及び中間体
US5028608A (en) * 1989-12-11 1991-07-02 The Trustees Of Princeton University N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
JPH04117381A (ja) * 1989-12-20 1992-04-17 Takeda Chem Ind Ltd 縮合複素環化合物,その製造法,用途及び中間体
JPH0578362A (ja) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd 縮合複素環化合物,その製造法,用途及び中間体
JPH05186437A (ja) * 1991-08-21 1993-07-27 Eisai Co Ltd 縮合ピリミジン誘導体
JPH06172358A (ja) * 1991-12-27 1994-06-21 Takeda Chem Ind Ltd 縮合ピリミジン誘導体、その製造法および用途
JP2000516961A (ja) * 1996-08-30 2000-12-19 イーライ・リリー・アンド・カンパニー 非古典的ピロロ[2,3―d]ピリミジン抗葉酸物質
CN101195625A (zh) * 2007-12-06 2008-06-11 上海交通大学 用于抗肿瘤药物抗叶酸剂及其盐和中间体
US20100081676A1 (en) * 2008-10-01 2010-04-01 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015031573; Parenti, Marco Daniele et al.: 'Three-Dimensional Quantitative Structure-Activity Relationship Analysis of a Set of Plasmodium falci' Journal of Medicinal Chemistry 47(17), 2004, 4258-4267 *
JPN6015031574; Kotake, Hoshihiko et al.: 'Novel 6-5 fused ring heterocycle antifolates with potent antitumor activity: bridge modifications an' Chemical & Pharmaceutical Bulletin 43(5), 1995, 829-841 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537107A (ja) * 2014-12-02 2017-12-14 イーライ リリー アンド カンパニー 1−オキソ−1,2−ジヒドロイソキノリン−7−イル−(5−置換−チオフェン−2−イル)−スルホンアミド化合物、それらの化合物を含む製剤、がん治療におけるaicarft阻害剤としてのそれらの使用

Also Published As

Publication number Publication date
CA2813743C (en) 2022-11-08
EP2627332A4 (en) 2014-08-20
CA2813743A1 (en) 2012-04-19
US20110082158A1 (en) 2011-04-07
WO2012051105A2 (en) 2012-04-19
EP2627332A2 (en) 2013-08-21
WO2012051105A3 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
USRE48731E1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2012327210B2 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR100840727B1 (ko) 아데노신 a1, a2a 및 a3 수용체 특이 화합물 및 그의 사용방법
US11053252B2 (en) Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
EA007254B1 (ru) Соединения, специфические к аденозиновому а, аи арецептору, и их применение
JP2021176820A (ja) キナゾリン化合物を有効成分とする医薬組成物
AU2002248151A1 (en) Compounds specific to adenosine A1, A2A, and A3 receptor and uses thereof
CA2813743C (en) Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
TWI546304B (zh) Protein tyrosine kinase inhibitors and their use
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
HK40048861B (en) Kras g12c inhibitors
HK40048861A (en) Kras g12c inhibitors
HK1259893B (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
HK1259893A1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160801